Back to Ovarian Cancer
NCT00262990
NCT00262990
Who may be able to join
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with ovarian, fallopian tube, or peritoneal cancer
- You have received no more than three rounds (regimens) of chemotherapy treatment
- Your most recent chemotherapy treatment included a platinum-based drug
Who may not be able to join:
- You currently have a bowel blockage (obstruction) that has not been treated or resolved
- You have received chemotherapy within the last 3 weeks
- You are currently recovering from any type of surgery
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Novartis Pharmaceuticals
Registry
clinicaltrials_gov
Start date
1 November 2005
Est. completion
1 February 2010
Where this trial is recruiting
🇦🇺 Australia
🇨🇦 Canada
🇩🇰 Denmark
🇫🇮 Finland
🇫🇷 France
🇬🇷 Greece
🇮🇹 Italy
🇵🇱 Poland
🇿🇦 South Africa
🇪🇸 Spain
🇬🇧 United Kingdom
🇺🇸 United States
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.